Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma.
Publication/Presentation Date
3-1-1998
Abstract
Cutaneous T-cell lymphoma (CTCL) is typically a skin-infiltrating, clonal proliferative disorder of CD4+ T cells that exhibit a T-helper type 2 cytokine phenotype. Therapeutic decisions are based on the extent of disease and the observations that host-antitumor responses occur and that these responses may be blunted by the immunosuppressive cytokines produced by the malignant T cells. Biologic response modifiers, which may enhance cell-mediated immunity and antitumor responses, are active agents in the treatment of CTCL. The rationale and use of biologic response modifiers to treat CTCL are reviewed in this article.
Volume
10
Issue
2
First Page
170
Last Page
174
ISSN
1040-8746
Published In/Presented At
Rook, A. H., Yoo, E. K., Grossman, D. J., Kao, D. M., Fox, F. E., & Niu, Z. (1998). Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Current opinion in oncology, 10(2), 170–174.
Disciplines
Medicine and Health Sciences
PubMedID
9555542
Department(s)
Department of Medicine
Document Type
Article